Adline Chem Lab to Consider September Results on November 5
Key highlights
- Adline Chem Lab’s board will consider September 2026 quarter and half-year results on November 5, 2026.
- Adline Chem Lab reported a net profit of ₹4.01 lakh in the quarter ended June 30, 2026.
- June 2026 quarter revenue from operations was ₹0.12 crore, compared with nil revenue a year earlier.
- The trading window will remain closed until 48 hours after the results announcement.
powered by IRIS

Adline Chem Lab Ltd will consider unaudited standalone financial results for the quarter and half year ended September 30, 2026, at its board meeting on November 5, following a ₹4.01 lakh net profit reported for the quarter ended June 30, 2026. The meeting is relevant because it will provide the next official update on the company’s financial performance.
Know Adline Chem Lab inside out
Results, valuation, peers and who's buying, in one view.
What will Adline Chem Lab’s board consider on November 5?
Adline Chem Lab’s board is scheduled to consider and approve the company’s unaudited standalone financial results for the quarter and half year ended September 30, 2026. The company informed the BSE of the meeting through an intimation dated October 30, 2026. Its BSE code is 524604.
The scheduled meeting covers the July-September 2026 quarter and the six-month period from April through September 2026. The disclosure does not state the expected revenue, profit, loss, expenses, cash position, or any operational target for the September quarter. Those details will be available only after the board considers and releases the results.
The company has also stated that its trading window remains closed until 48 hours after the financial results are announced. This is part of the company’s stated compliance process around the publication of unpublished price-sensitive information.
What was Adline Chem Lab’s latest reported financial performance?
Adline Chem Lab reported a net profit after tax of ₹4.01 lakh for the quarter ended June 30, 2026, compared with a net loss of ₹5.13 lakh in the corresponding quarter of the prior fiscal year. Revenue from operations for the June 2026 quarter was ₹0.12 crore, compared with nil revenue in the comparable quarter a year earlier.
The June-quarter results were unaudited standalone numbers. According to the disclosed information, the Audit Committee reviewed the results and the board approved them on August 13, 2026. The statutory auditors conducted a limited review and did not report qualifications or modifications.
For the financial year ended March 31, 2026, Adline Chem Lab reported a net loss of ₹28.11 lakh on revenue of ₹0.01 crore. The June 2026 result therefore marked a return to quarterly profitability, although the September-quarter filing will be required to show whether the company maintained that position in the next reporting period.
Got a follow-up? Ask IRIS
How did the September-results process unfold?
Adline Chem Lab announced on October 30 that the board would meet on November 5 to consider the September 2026 quarter and half-year results. The announcement was made ahead of the meeting and identified the proposed agenda as approval of unaudited standalone financial results.
The November meeting follows the company’s earlier reporting cycle. The board considered and approved unaudited standalone results for the quarter ended June 30, 2026, on August 13, 2026. It had also approved unaudited standalone results for the quarter and half year ended September 30, 2025, at a meeting held on November 12, 2025.
The available disclosure does not indicate any change in the scope of the November 5 agenda beyond the consideration and approval of the September 2026 results. It also does not provide an advance earnings estimate, management commentary, or a declared corporate action.
Why do the September results matter to investors?
The September results matter because they will cover the first half of the 2026-27 financial year and provide the next set of reported figures after the June-quarter profit. Investors will be able to compare the new numbers with the June 2026 quarter, when revenue from operations was ₹0.12 crore and net profit was ₹4.01 lakh.
The half-year disclosure will also provide a clearer view of performance after the loss reported for the year ended March 2026. Revenue, profitability, expenses, and any notes accompanying the unaudited standalone statements will be important for assessing the reported financial trend. The current announcement itself does not establish whether the June-quarter performance continued into the September quarter.
Adline Chem Lab has not disclosed segment information because Ind AS 108 was stated to be not applicable. As a result, investors reviewing the September filing will have to rely on the standalone financial statements and accompanying notes for the available detail on the business.
Conclusion
Adline Chem Lab is scheduled to place its unaudited standalone September 2026 quarter and half-year results before the board on November 5. The filing follows a June 2026 quarter in which the company reported ₹0.12 crore in revenue from operations and a ₹4.01 lakh net profit, compared with nil revenue and a loss in the comparable prior-year quarter.
The next item to watch is the outcome of the November 5 board meeting and the subsequent financial-results disclosure. Investors can review the reported half-year revenue, profit or loss, expenses, auditor review and any notes issued with the standalone results, while the trading window is set to reopen 48 hours after the announcement.


